1133 related articles for article (PubMed ID: 34525276)
1. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
[No Abstract] [Full Text] [Related]
2. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
Liu Y; Liu J; Xia H; Zhang X; Zou J; Fontes-Garfias CR; Weaver SC; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Jul; 385(5):472-474. PubMed ID: 33979486
[No Abstract] [Full Text] [Related]
3. Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
Terpos E; Trougakos IP; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Bagratuni T; Papanagnou ED; Patseas D; Gumeni S; Malandrakis P; Korompoki E; Dimopoulos MA
Am J Hematol; 2021 Sep; 96(9):E321-E324. PubMed ID: 34028867
[No Abstract] [Full Text] [Related]
4. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune Humans.
Forgacs D; Jang H; Abreu RB; Hanley HB; Gattiker JL; Jefferson AM; Ross TM
Front Immunol; 2021; 12():728021. PubMed ID: 34646267
[TBL] [Abstract][Full Text] [Related]
6. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.
Lustig Y; Nemet I; Kliker L; Zuckerman N; Yishai R; Alroy-Preis S; Mendelson E; Mandelboim M
N Engl J Med; 2021 Jun; 384(25):2453-2454. PubMed ID: 33826815
[No Abstract] [Full Text] [Related]
7. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
8. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
9. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
Hall VG; Ferreira VH; Ku T; Ierullo M; Majchrzak-Kita B; Chaparro C; Selzner N; Schiff J; McDonald M; Tomlinson G; Kulasingam V; Kumar D; Humar A
N Engl J Med; 2021 Sep; 385(13):1244-1246. PubMed ID: 34379917
[No Abstract] [Full Text] [Related]
10. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
Manisty C; Otter AD; Treibel TA; McKnight Á; Altmann DM; Brooks T; Noursadeghi M; Boyton RJ; Semper A; Moon JC
Lancet; 2021 Mar; 397(10279):1057-1058. PubMed ID: 33640038
[No Abstract] [Full Text] [Related]
11. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants.
Jalkanen P; Kolehmainen P; Häkkinen HK; Huttunen M; Tähtinen PA; Lundberg R; Maljanen S; Reinholm A; Tauriainen S; Pakkanen SH; Levonen I; Nousiainen A; Miller T; Välimaa H; Ivaska L; Pasternack A; Naves R; Ritvos O; Österlund P; Kuivanen S; Smura T; Hepojoki J; Vapalahti O; Lempainen J; Kakkola L; Kantele A; Julkunen I
Nat Commun; 2021 Jun; 12(1):3991. PubMed ID: 34183681
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence.
Daungsupawong H; Wiwanitkit V
Semergen; 2024; 50(4):102132. PubMed ID: 38295632
[No Abstract] [Full Text] [Related]
13. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
[No Abstract] [Full Text] [Related]
14. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
15. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
16. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
17. The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E; Davidovic T; Schimpf J; Abbassi-Nik A; Mutschlechner B; Ulmer H; Benda MA; Sprenger-Mähr H; Winder T; Lhotta K
Front Immunol; 2021; 12():704773. PubMed ID: 34220867
[TBL] [Abstract][Full Text] [Related]
18. Plasma Neutralization of the SARS-CoV-2 Omicron Variant.
Schmidt F; Muecksch F; Weisblum Y; Da Silva J; Bednarski E; Cho A; Wang Z; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
N Engl J Med; 2022 Feb; 386(6):599-601. PubMed ID: 35030645
[No Abstract] [Full Text] [Related]
19. Neutralizing Activity of BNT162b2-Elicited Serum.
Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
[No Abstract] [Full Text] [Related]
20. Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
Zhao X; Li D; Ruan W; Chen Z; Zhang R; Zheng A; Qiao S; Zheng X; Zhao Y; Dai L; Han P; Gao GF
N Engl J Med; 2022 Mar; 386(9):894-896. PubMed ID: 35081296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
